Medtronic Resolute Drug-Eluting Stent Shows Strong Results, Even in Challenging Diabetes Patients with Coronary Disease - WisdomTree U.S. SmallCap Dividend Fund (ARCA:DES), Medtronic (NYSE:MDT)

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.

Currently under review by the U.S. Food and Drug Administration, the Resolute® drug-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT) continues to demonstrate consistently positive performance across a variety of studies, according to two new data analyses being presented this week at TCT 2011. The first analysis, RESOLUTE Pooled Diabetics, focuses on outcomes in patients with both coronary artery disease and diabetes, two common comorbidities; the second, RESOLUTE Pooled Safety, focuses on safety outcomes across all patient types.

27% profits every 20 days?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!